newsfilter
← Latest News
GlobeNewswire·

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine, IO102-IO103, in